Categories: Finances

Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in Wet Age-Related Macular Degeneration

EYLEA HD shows sustained vision and anatomical improvements over three years, allowing extended dosing intervals in wAMD patients.

Source link

nasdaqpicks.com

Recent Posts

Equity inflows dip 4% on market volatility

The inflows into mutual fund equity schemes dipped four per cent last month to ₹39,688…

3 minutes ago

Ashok Leyland Q3 Results: Net profit improves 32% YoY to ₹762 crore

Ashok Leyland, the Indian flagship of the Hinduja Group announced its December quarter performance today,…

5 minutes ago

Close Brothers to set aside £165mn for car finance probe

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…

6 minutes ago

Swiss packaging entity, SIG commissions its first aseptic carton plant in Gujarat; plans Phase-2 expansion

In order to tap the opportunities arising from rapidly growing dairy and non-carbonated soft drink…

11 minutes ago

Varun Beverages stock fizzled out despite strong earnings. Here’s why

The company's profits surged 36% year-on-year (YoY) to ₹196 crore, and total revenue soared 38%…

16 minutes ago

PM Surya Ghar Muft Bijlee Yojana: Free electricity for all? Not Quite

On 13 February 2024, the Union Government unveiled an ambitious initiative—PM Surya Ghar Muft Bijlee…

18 minutes ago